KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial.

Vanita Noronha, Minit Shah, Akhil Kapoor, Nandini Menon, Vijay Patil, Akhil Rajendra Kurup, Amrit Dhar, Supriya Goud, Sucheta More, Akanksha Yadav, Archi Agarwal, Nilesh Sable, Nitesh Chavan, Anupama Pradosh, Aditi Shirsat, Vikram Gota, Ankush Shetake, Sonal Sharma, Bal Krishna Mishra, Anuj Gupta, Bipinesh Sansar, Sunita Sonawane, Kumar Prabhash

JCO Glob Oncol 12(4) e2500505

PMID42024845
PMCID-
DOI10.1200/GO-25-00505
发表日期2026-04-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

PURPOSE: Abiraterone acetate (AA) is widely used for metastatic castration-resistant prostate cancer (mCRPC), but the standard dose (1000 mg fasting) imposes challenges in resource-constrained settings due to strict fasting requirements and financial toxicity. Pharmacokinetic (PK) studies suggest that low-dose AA (250 mg with a low-fat meal) may provide comparable drug exposure, although clinical evidence remains limited. This trial compared the clinical efficacy of low-dose versus standard-dose AA. MATERIALS AND METHODS: This multicenter, open-label, phase III, noninferiority trial randomly assigned patients with mCRPC, 1:1, to low-dose or standard-dose AA. The primary end point was prostate-specific antigen progression-free survival (PSA-PFS). Secondary/exploratory end points included PSA30/PSA50 responses (% of patients with ≥30% or ≥50% reduction in PSA), radiographic PFS, overall PFS, overall survival (OS), quality of life (QoL), and PK. Planned sample size of 314 (on the basis of a noninferiority margin of hazard ratio, 1.37) was not achieved because of slow accrual, so the noninferiority hypothesis could not be tested. RESULTS: A total of 164 patients were enrolled between September 2020 and January 2025 (median age 65 years; 64.0% received prior docetaxel). PSA30 and PSA50 responses were 50.0% and 38.5% with low-dose AA versus 55.4% (P = .505) and 45.9% (P = .350) with standard-dose AA, respectively. Median follow-up was 17.5 months. Median PSA-PFS was 5.7 months with low-dose versus 3.8 months (P = .830) with standard-dose AA. Median OS was 18.1 versus 15.8 months (P = .976). Grade ≥3 toxicities occurred in 38.3% versus 30.0% (P = .269), respectively. PK analyses demonstrated approximately 8-fold higher AA exposure with standard dose. QoL scores were comparable between arms. CONCLUSION: Although underpowered to prove noninferiority, low-dose AA with food yielded outcomes broadly similar to standard dosing, with maintained safety and QoL. This cost-conscious regimen may be a feasible alternative, supporting further confirmatory evaluation.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。